Obesity is a risk factor for atrial fibrillation. Whether weight reduction and cardiometabolic risk factor management can reduce the burden of atrial fibrillation is not known.
study has demonstrated a direct effect of obesity on the atrial substrates. 11 We therefore evaluated the effect of a structured weight reduction and risk factor management program on atrial fibrillation burden in a randomized controlled trial.
Methods

Study Population
Patients were recruited from the Centre for Heart Rhythm Disorders at the University of Adelaide, Adelaide, Australia. Inclusion criteria were symptomatic paroxysmal or persistent atrial fibrillation (in sinus rhythm at enrollment); body mass index (BMI) greater than 27 (calculated as weight in kilograms divided by meters squared); waist circumference greater than 100 cm (men) or greater than 90 cm (women); and age 21 to 75 years. Exclusion criteria included recent participation (within 3 months) in a weight loss program; unstable international normalized ratio (INR); diabetes necessitating insulin; significant cardiac valvular disease, and inability to provide informed consent (details in eTable 1 in Supplement). Patients were censored if they underwent ablation of atrial fibrillation or atrioventricular-node ablation. All patients provided written informed consent to the study protocol approved by the human research ethics committee of the Royal Adelaide Hospital and the University of Adelaide.
Study Protocol and Design
This single-center, partially blinded, randomized controlled trial, with a median 15-months' follow-up, randomized patients to either a physician-led weight loss program (intervention group) or to self-directed general lifestyle measures (control group). Both groups underwent intensive management of cardiometabolic risk factors. A software-based obesity management system (OBEMAN) developed at the University of Adelaide was used to assess and monitor patients undergoing a tailored weight loss program. Patients were evaluated at 3-month intervals.
Study Blinding
Study coordinators, treating physicians, and other personnel, with the exception of weight loss counselors, were blinded to randomization, and patients were instructed not to disclose their status. Patient records contained generic statements without indicating group allocation.
Weight Management
Intervention Group | The 2 phases of the program, weight loss and weight maintenance, followed a previously described approach. 12 Weight loss was induced over 8 weeks using a modified very-low-calorie diet (800-1200 kcal/d). Patients were prescribed very-low-calorie meal replacement sachets (Prima Health Solutions) for 2 of their daily meals. The third meal consisted of calorie-controlled foods with high levels of animal and plant proteins and low glycemic index. A written exercise plan prescribed low-intensity exercise (walking or cycling), initially for 20 minutes 3 times weekly and then increasing to 45 minutes 3 times weekly.
Very low-calorie meals were gradually phased out and replaced with low-glycemic index meals, exercise intensity uptitration, and behavioral modification, 13 for the following 13 months. Goal-directed face-to-face clinic visits were scheduled every 3 months. Participants scheduled additional visits as required and were provided 24-hour e-mail and telephone support. Participants in the intervention group were required to maintain a diet, activity, and blood pressure diary.
Control Group | Written and verbal nutrition and exercise advice was provided at enrollment. Fish oil (3 g/d) was prescribed except for participants taking dual antiplatelet agents or oral anticoagulants. Completion of a diet and activity diary was not requested.
Outcomes
The primary outcome was atrial fibrillation symptom burden, quantified using the Atrial Fibrillation Severity Scale (AFSS) (eFigure 9 in Supplement). The AFSS is a validated scale (range, 3.25 [single minimally symptomatic episode lasting minutes] to 30 [continuous highly symptomatic episode lasting >48 hours]) that encompasses 3 domains of atrial fibrillation: event frequency (scored 1-10), duration (scored 1.25-10), and global episode severity (scored 1-10).
14 In addition, the AFSS assesses symptom severity via an associated symptom-specific continuous subscale (range, 0 [no symptoms] to 35 [severe symptomatology]). The secondary outcomes were 7-day Holter-derived atrial fibrillation episode and duration burden, echocardiographic left atrial area, and left ventricular wall thickness.
Anthropometry
A stadiometer and digital scales were used to record height and weight in light clothing without shoes. Waist circumference was measured at the midpoint between the iliac crest and the lowest rib, and BMI was calculated. Anthropometric values were measured at 3-month intervals.
Management of Cardiometabolic Risk Factors
Hypertension, hyperlipidemia, glucose intolerance, sleep apnea, and alcohol and tobacco use were screened for and managed in both groups. If fasting glucose level was between 100 mg/dL (5.55 mmol/L) and 125 mg/dL (6.94 mmol/L), a 2-hour oral glucose Patients were asked to measure blood pressure 2 to 3 times daily at home using an appropriately sized cuff. For each recording, measurements were performed 3 times, and the mean was recorded. Hypertension was treated using reninangiotensin-aldosterone system antagonists preferentially. Other agents were added to achieve a resting blood pressure less than 130/90 mm Hg. Ambulatory blood pressure monitoring (24-hour) was performed if home and clinic measurements were discrepant. Changes in pharmacotherapy were recorded at each visit. Fasting blood was drawn at enrollment and follow-up for measurement of serum lipids, C-reactive protein (CRP), insulin, and glucose levels, using previously described methods. 16 All patients underwent laboratory-based polysomnography, with scoring using standard criteria.
17, 18 Patients with moderate-severe obstructive sleep apnea (apnea-hypopnea index >30 episodes/h) were offered continuous positive airway pressure. Those with an apnea-hypopnea index of 15 episodes/h to 30 episodes/h were offered treatment based on the degree of hypersomnolence, cardiovascular risk, and nocturnal oxygen desaturation. Written and verbal counseling was provided for smoking cessation and alcohol reduction. An ultimate goal of alcohol reduction (≤30 g/wk) or abstinence was set a priori.
Antiarrhythmic Pharmacotherapy
Antiarrhythmic agents were prescribed for rate control, rhythm control, or both at the discretion of the treating physician. Changes were documented at each visit.
Atrial Fibrillation
The AFSS questionnaire was administered at baseline and 3-month intervals. Holter recordings were obtained at baseline and repeated at 12 months. Analysis was performed by 2 independent scientists blinded to participant randomization. Any episode of atrial arrhythmia lasting 30 seconds or longer was considered atrial fibrillation. Total duration of atrial fibrillation was the cumulative sum of all discrete episodes.
Cardiac Structure
Transthoracic echocardiography was performed with a 3.5-MHz probe (Vivid7, GE Medical Systems) at baseline and at 12-month follow-up to measure left atrial area and left ventricular wall thickness. Left ventricular mass was calculated from the posterior wall thickness, septal wall thickness, and left ventricular end-diastolic dimension as recommended by the American Society of Echocardiography. 19 .0) and 13.5 (SD, 6.6), respectively. A mean reduction of 7.6 in the absolute atrial fibrillation symptom burden score resulted in clinically meaningful benefits in the group with sinus rhythm maintenance. Therefore, we estimated a baseline atrial fibrillation burden score of 13 in each group. In addition, with the anticipation of a worst-casescenario 35% attrition rate, 21 enrolling 178 patients would achieve 85% power to detect a 30% difference in atrial fibrillation symptom burden score between groups at last follow-up, for a 2-sided α of .05. Eligible patients were randomized in a 1:1 ratio to either group using SPSS version 17 (IBM SPSS Inc).
Data Analysis
Differences in outcomes were determined within each group and between the 2 study groups on an intention-to-treat basis. Continuous variables are presented as mean and 95% CI or mean and standard deviation (SD) when normally distributed on visual inspection of their histograms and as median (interquartile range) when not normally distributed. Categorical variables are summarized as count (proportion). For repeated-measures analysis of continuous dependent variables, mixed-effects modeling was used, with patient identity included as a random effect. Randomization group was entered into the mixed model as part of an interaction term with patients' visit time. If this group × time interaction term was significant, it was retained in the model, implying that the influence of randomization group on the outcome variable was time dependent. Post hoc testing was performed to determine whether the group influence on the dependent variable was significant at each visit.
For repeated-measures analysis of binary and nonnormal dependent variables, an analogous approach was adopted using generalized estimating equations. A binomial probability distribution with logit link function or a Poisson distribution with log link function were assumed as appropriate, as was an autoregressive correlation structure. Post hoc logistic regression was used to determine whether group allocation was predictive of subsequent need for radiofrequency catheter ablation.
To account for atrial fibrillation ablations performed on participants, we performed sensitivity analyses, because these procedures may be regarded as a clinically relevant outcome and may alter the burden of atrial fibrillation in a given individual. In the first sensitivity analysis, AFSS scores and Holter data were imputed to baseline values for the time points following the ablation. In the second sensitivity analysis, these variables were imputed to the preablation value. In the third analysis, those control participants who underwent ablation of atrial fibrillation were excluded. To determine the influence of dropouts on the study findings, a further sensitivity analysis was performed. For AFSS scores, differences between final and baseline scores were regressed against patient randomization group as a predictor variable. We determined the effect on the regression coefficients of varying the missing AFSS scores in the intervention group, the control group, or both. The range of the sensitivity analysis encompassed 1 SD of the AFSS score variable. For Holter data we used a binary end point of freedom from atrial fibrillation.
All statistical tests were 2-sided, and P < .05 was considered statistically significant. Analyses were performed using STATA version 12.1 (Stata Corp).
Results
Study Participants, Baseline Characteristics, and Follow-up
Of consecutive patients with a BMI greater than 27 (n = 248), 178 were eligible and provided consent. Of these, 28 (10 in the intervention group and 18 in the control group) withdrew prior to the program initiation. The final cohort therefore included 150 patients; 75 in the intervention group and 75 in the control group ( Figure 1 ). Mean follow-up was 12.9 (95% CI, 12.3-13.5) months in the intervention group and 12.0 (95% CI, 11.1-12.9) months in the control group (median, 15 months for both groups). At 12 months, 109 (73%) had completed the study (57 in the intervention group and 52 in the control group). By 15 months, 81 (54%) remained (42 in the intervention group and 39 in the control group). Of the 69 not completing 15 months' follow-up, 23 underwent catheter ablation (10 in the intervention group [6 at 12 months and 3 at 15 months] and 14 in the control group [6 at 9 months, 2 at 12 months, and 6 at 15 months]). One patient in the intervention group underwent atrioventricular-node ablation and pacemaker implantation at 15 months. Patients undergoing ablation were removed from further analysis immediately after undergoing the procedure. Baseline characteristics were similar in both groups ( Table 1) .
Anthropometrics
Weight, BMI, and waist circumference decreased in both groups but significantly more in the intervention group ( Table 2) . Differences were evident by 3 months and persisted for the remainder of follow-up; P < .001 for group × time interaction for all measures (Figure 2 and eFigure 1 in Supplement).
Atrial Fibrillation
Atrial Fibrillation Severity Atrial fibrillation symptom burden and symptom severity scores all declined in both the intervention and the control groups (P ≤ .01, both domains) ( (Figure 3 ). Secondary analysis for AFSS symptom frequency, duration, and global episode severity scores showed significantly greater decline in the intervention group compared with the control group (group × time interaction, P < .001 for all 3 subscales) ( Table 2 and eFigure 2 in Supplement).
Continuous Rhythm Monitoring
Holter recordings were undertaken at baseline and at 12 months among 109 patients (57 in the intervention group, 52 in the control group) ( Tables 1 and 2 ). The mean number of atrial fibrillation episodes in the intervention group decreased from 3.3 (95% CI, 1.6-4.9) to 0.62 (95% CI, 0.19-1.0), and the duration of atrial fibrillation decreased from 1176 (95% CI, 720-1632) minutes to 491 (95% CI, 159-822) minutes. In the control group, the mean number of atrial fibrillation episodes was 2.8 (95% CI, 1.7-4.0) at baseline and 2.0 (95% CI, 1.1-3.0) at 12 months, and the duration of atrial fibrillation increased from 1393 (95% CI, 785-1994) minutes to 1546 (95% CI, 782-2308) minutes. Both measures showed significant group differences (group × time interaction, P < .001). After adjustment for baseline BMI, duration of atrial fibrillation disease, longest atrial fibrillation episode, and atrial fibrillation type, the probability of having 1 or more atrial fibrillation episodes between baseline and follow-up remained lower in the intervention group (0. 
Intervention Uptake, Pharmacotherapy, and Risk Factor Modification
From enrollment to study conclusion there was an increase in patients consuming fish oil (controls, 3 to 55), metformin (intervention group, 1 to 15; control group, 2 to 11), and hypolipidemic agents (intervention group, 16 to 44; control group, 23 to 44) and an increase in use of continuous positive airway pressure (intervention group, 5 to 21; control group, 7 to 23) (eFigure 3 in Supplement) (P < .001 for all interventions in both groups). There was a decrease in numbers of patients with elevated blood pressure (intervention group, 64 to 16; control group, 67 to 44), elevated lipid levels (intervention group, 51 to 13; control group, 58 to 30), and alcohol consumption greater than 30 g/wk (intervention group, 25 to 4; control group, 28 to 16) (P < .001 for all risk factors in both groups).
There was a greater decline in excessive alcohol consumption as defined a priori in the intervention group than in the control group (P = .01). There was a reduction in systolic and diastolic blood pressure in the intervention group 05 for systolic and P = .03 for diastolic), with a significant effect of group allocation at 15 months (P < .001 for systolic and P = .02 for diastolic). Use of antihypertensive agents , with significant effect of group allocation at 15 months (P < .001). Levels of serum glucose (P < .001), insulin (P < .001), CRP (P < .001), and total and low-density lipoprotein cholesterol (P < .001) decreased and of high-density lipoprotein cholesterol (P < .001) increased in both groups. Levels of serum triglycerides decreased only in the intervention group (P < .001). Levels of insulin (P < .001) and CRP (P < .001) decreased more in the intervention group than in the control group (Table 2) .
Safety
Adverse events are outlined in eTable 7 in Supplement. Instability in INR was observed, with 1 patient withdrawn for a persistent INR less than 2.0 and another for an INR greater than 4. No serious bleeding was observed in either group. Postural symptoms, which frequently occurred with systolic blood pressure less than 100 mm Hg or a postural decrease greater than 10 mm Hg, resolved with reduction in use of antihypertensive agents. Error bars indicate 95% confidence intervals. A, Between-group level of significance: P = .41 at time 0, P = .12 at 3 months, P < .001 at 6, 9, 12, and 15 months. B, Between-group level of significance: P = .49 at time 0, P = .17 at 3 months, P < .001 at 6, 9, 12, and 15 months. Error bars indicate 95% confidence intervals. BMI indicates body mass index, calculated as weight in kilograms divided by height in meters squared. A, Between-group level of significance: P = .21 at time 0, P = .01 at 3 months, P < .001 at 6, 9, 12, and 15 months. B, Between-group level of significance: P = .13 at time 0, P < .001 at 3, 6, 9, 12, and 15 months.
Catheter Ablation Management of Atrial Fibrillation
Catheter ablation was undertaken in 14 patients in the control group (all ablation of atrial fibrillation) compared with 10 in the intervention group (9 ablation of atrial fibrillation and 1 atrioventricular-node ablation). There was no significant reduction in the need for ablation in the intervention group (odds ratio, 0.67 [95% CI, 0.28-1.6]; P = .41); however, this study was not designed or powered to examine the effects on need for catheter ablation. To address the effects of catheter ablation on atrial fibrillation, sensitivity analyses were performed for the primary outcomes following the exclusion of controls who underwent ablation of atrial fibrillation and indicated unchanged study findings (eTable 3 in Supplement). Given the differential timing as well as likelihood of catheter ablation in each group and that in many cases ablation likely represented treatment failure, sensitivity analyses were conducted treating catheter ablation as a treatment failure. A moderately conservative approach would be to impute return to baseline symptoms score. The least conservative approach would be to impute last measured symptom score before ablation. In the first analysis, atrial fibrillation symptom burden score, symptom severity score, episode frequency score, episode duration score, and global episode severity score, as well as atrial fibrillation cumulative duration (of all episodes on Holter recording) and the occurrence of any atrial fibrillation episode (≥30 seconds on Holter recording) were imputed as baseline values from the time of any procedure for ablation of atrial fibrillation (eFigure 7 in Supplement). This did not change the significance of the difference between the intervention and the control groups.
In the second analysis we imputed the last AFSS score prior to the ablation (eFigure 8 in Supplement). This analysis similarly did not alter the finding of a significant benefit in favor of the intervention group.
Patient Dropout and Sensitivity Analysis
Descriptive analysis of the dropout population is shown in eTable 5 and eTable 6 in Supplement. For AFSS frequency, departures of ±2 points could be tolerated and for AFSS episode severity, departures of ±1 point could be tolerated, without loss of advantage in the intervention group in these subscales. For AFSS duration, the intervention group's advantage was maintained for all departures from missing at random tested. For AFSS symptom severity subscale, departures from missing at random up to ±3 points among either the intervention or the control group could be tolerated before coefficient 95% confidence limits crossed zero and statistically significant advantage of the treatment group allocation was lost. The outcomes of this sensitivity analysis are shown in eFigure 6A-F in Supplement. For ambulatory rhythm monitoring, at all tested values of informatively missing odds ratios from 0 to 1, this result remained consistently in favor of the treatment group. Furthermore, in addition to the reduction in the number of atrial fibrillation episodes and their duration on ambulatory rhythm recording, in the intervention group there was a reduction in the proportion of patients experiencing at least 1 episode. This observation is in keeping with the results of the atrial fibrillation severity scores and unlikely to represent a skewed effect from a subgroup of the cohort. In addition, the patient's decision to undergo a catheter ablation (a study censorship criterion) was symptom driven.
Discussion
In this study, a structured weight management program for highly symptomatic patients with atrial fibrillation reduced symptom burden and severity and reduced antiarrhythmic use when compared with attempts to optimally manage risk factors alone. The beneficial effects may be attributable to decrease in left atrial area and ventricular wall thickness, thereby reducing the left atrial hypertension that is a common finding in obese patients. 22 Epidemiologic data suggest a 4% to 5% increased risk of developing atrial fibrillation w ith each 1-unit BMI increment. 23, 24 The greater reduction in BMI of 3.5 units in the intervention group was accompanied by improvement in other risk factors. Obesity, hypertension, impaired glucose tolerance or diabetes mellitus, and obstructive sleep apnea are closely interrelated conditions previously identified as independent risk markers for atrial fibrillation. As observed in the current and prior studies, an active intervention directed primarily at weight loss has a favorable effect on all of these conditions. Hypertension is estimated to increase the risk of atrial fibrillation by 70% to 80%. 25 The effect of hypertension management on atrial fibrillation outcomes has been previously evaluated in different patient groups. Most, but not all, 26 studies suggest a modest preventive effect on atrial fibrillation when renin-angiotensin active agents 27 are used in the presence of structural heart disease, 28 including left ventricular hypertrophy, or following cardioversion. 29 These studies have not examined the concurrent management of comorbid conditions often seen in patients with hypertension, such as sleep apnea and alcohol consumption. 30 Furthermore, the influence of alcohol consumption on risk of atrial fibrillation was estimated by Kodama et al 31 as 8% per 10-g daily consumption increment, without a safe consumption threshold. Sparse mechanistic studies have suggested atrial conduction abnormalities with low-dose alcohol, 32 thus warranting its consideration as an independent risk factor associated with atrial fibrillation. Therefore, individually and in association, hypertension and alcohol consumption may represent modifiable risk factors imparting a substantial risk of atrial fibrillation. Although no significant association between insulin resistance and atrial fibrillation has been defined, 33 diabetes mellitus has been shown to increase the risk of new-onset atrial fibrillation by 50%. 34 This may be the result of the effects of plasma insulin and an obesogenic diet on myocardial energetics and function. 35 Additionally, an independent association between CRP level and atrial fibrillation has been established, with a 36% increased risk with each CRP-level tertile increment. 36 In our cohort, we observed a 20.26-μIU/mL (95% 
Study Limitations
Although the study did not achieve the desired sample size, the randomization of 150 participants provided at least 80% power to meet the study's primary end point. The recruitment shortfall was offset by the magnitude of weight loss and reduction in the atrial fibrillation symptom burden scores in the intervention group. The study was conducted at a single center, with a highly motivated predominantly white male (67%) population. There were a number of dropouts, but they were similar between groups, and sensitivity analysis indicates that our findings in favor of the intervention group are robust, even in the face of imbalanced participant dropout. The use of the AFSS to assess the atrial fibrillation symptom burden has the potential to underestimate the true arrhythmia burden, and periodic assessment with 7-day continuous Holter monitoring may miss episodes during the nonmonitored period. An implanted loop recorder may provide a more accurate assessment of arrhythmia burden. However, the combination of 7-day continuous ambulatory recording and a validated questionnaire may have wider clinical applicability in an ambulatory setting, combining objective and subjective parameters. Last, the weight loss program counselors could not be blinded to the patient allocation. Although we believe other clinical care providers and study coordinators were unaware of patient group allocation, this was not formally assessed.
Conclusions
Atrial fibrillation significantly affects quality of life and survival. 42 Our results suggest that weight reduction and improvement of multiple cardiometabolic risk factors benefited cardiac structure, reduced atrial fibrillation events observed on ambulatory rhythm recordings, and reduced atrial fibrillation symptom burden. The lifestyle and comprehensive metabolic risk factor management program was feasible to deliver, effective, associated with a limited risk of serious adverse events, and resulted in a substantial reduction in the symptom burden and symptom severity of atrial fibrillation.
